解读欧美指南——再议新型P2Y12抑制剂治疗地位

被引：4

作者：

郭新贵

机构：

[1] 上海华东医院心内科

来源：

中国介入心脏病学杂志 | 2015年 / 23卷 / 01期

关键词：

指南解读; 新型P2Y12抑制剂;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

<正>动脉粥样硬化继以血小板激活、聚集导致血栓形成是冠心病急性缺血事件的主要发生机制,因此,抗血小板药物治疗是防治冠心病的重要手段。阿司匹林仍是目前治疗的基石,其与氯吡格雷的联合应用是经皮冠状动脉介入治疗(PCI)术后双联抗血小板治疗的标准方案,但广泛应用易增加出血风险、药物抵抗及外科术前桥接等问题仍困扰临床。以普拉格雷和替格瑞洛为代表的新型P2Y12抑制剂应运而

引用

页码：55 / 58

页数：4

共 8 条

[1] 2013 ESC guidelines on the management of stable coronary artery disease
Montalescot, Gilles
Sechtem, Udo
Achenbach, Stephan
Andreotti, Felicita
Budaj, Andrzej
Bugiardini, Raffaele
Crea, Filippo
Cuisset, Thomas
Di Mario, Carlo
Rafael Ferreira, J.
Gersh, Bernard J.
Gitt, Anselm K.
Hulot, Jean-Sebastien
Marx, Nikolaus
Opie, Lionel H.
Pfisterer, Matthias
Prescott, Eva
Ruschitzka, Frank
Sabate, Manel
Senior, Roxy
Taggart, David Paul
van der Wall, Ernst E.
Vrints, Christiaan J. M.
Knuuti, Juhani
Valgimigli, Marco
Bueno, Hector
Claeys, Marc J.
Donner-Banzhoff, Norbert
Erol, Cetin
Frank, Herbert
Funck-Brentano, Christian
Gaemperli, Oliver
Gonzalez-Juanatey, Jose R.
Hamilos, Michalis
Hasdai, David
Husted, Steen
James, Stefan K.
Kervinen, Kari
Kolh, Philippe
Kristensen, Steen Dalby
Lancellotti, Patrizio
Maggioni, Aldo Pietro
Piepoli, Massimo F.
Pries, Axel R.
Romeo, Francesco
Ryden, Lars
Simoons, Maarten L.
Sirnes, Per Anton
Steg, Ph. Gabriel
Timmis, Adam
[J]. EUROPEAN HEART JOURNAL, 2013, 34 (38) : 2949 - +
[2] Antiplatelet therapy: new pharmacological agents and changing paradigms[J] . D. Capodanno,J. L. Ferreiro,D. J. Angiolillo.J Thromb Haemost . 2013
[3] 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J] . Hani Jneid,Jeffrey L. Anderson,R. Scott Wright,Cynthia D. Adams,Charles R. Bridges,Donald E. Casey,Steven M. Ettinger,Francis M. Fesmire,Theodore G. Ganiats,A. Michael Li
[4] Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis[J] . Circulation . 2010 (21)
[5] Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial[J] . Shamir R Mehta,Jean-Francois Tanguay,John W Eikelboom,Sanjit S Jolly,Campbell D Joyner,Christopher B Granger,David P Faxon,Hans-Jurgen Rupprecht,Andrzej Budaj,Alvaro Avezum,Petr Widimsky,Philippe Gabriel Steg,Jean-Pierre Bassand,Gilles Montalescot,Carlos Macaya,Giuseppe Di
[6] Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial[J] . Gilles Montalescot,Stephen D Wiviott,Eugene Braunwald,Sabina A Murphy,C Michael Gibson,Carolyn H McCabe,Elliott M Antman.The Lancet . 2009 (9665)
[7] Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial[J] . The Lancet . 2005 (9497)
[8] Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study[J] . Shamir R Mehta,Salim Yusuf,Ron JG Peters,Michel E Bertrand,Basil S Lewis,Madhu K Natarajan,Klas Malmberg,Hans-Jürgen Rupprecht,Feng Zhao,Susan Chrolavicius,Ingrid Copland,Keith AA Fox.The Lancet . 2001 (9281)

← 1 →